We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 May 2021 - 26 May 2021
Virtual Venue
25 May 2021 - 28 May 2021

Toxoplasmic Encephalitis in HIV Patients Detected in Urine

By LabMedica International staff writers
Posted on 25 Mar 2021
Print article
Image: The EASY-nLC 1200 HPLC, high-throughput capacity in a nano-flow UHPLC (Photo courtesy of Thermo Fisher Scientific)
Image: The EASY-nLC 1200 HPLC, high-throughput capacity in a nano-flow UHPLC (Photo courtesy of Thermo Fisher Scientific)
Toxoplasma encephalitis (TE) is the most commonly reported neurological opportunistic infection in human immunodeficiency virus (HIV)-infected patients since the introduction of combination ART (cART). Diagnosis of TE is challenging under the best clinical circumstances.

The poor clinical sensitivity of quantitative polymerase chain reaction (qPCR) for Toxoplasma gondii in blood and cerebrospinal fluid (CSF) and the limited availability of molecular diagnostics and imaging technology leaves clinicians in resource-limited settings with few options other than empiric treatment.

An international team of scientists led by the University of Illinois Chicago (Chicago, IL, USA) recruited in a study 164 HIV positive patients from Peru and Bolivia and 51 ambulatory HIV/T. gondii positive patients for controls. Blood and urine specimens were taken at enrollment, which for most hospitalized patients was shortly after admission; remnant CSF was collected if the subject underwent lumbar puncture as part of their medical care. CD4 and CD8 cell counts and viral loads were abstracted from participants’ charts.

The investigators have described a proof of concept for novel urine diagnostics for TE using Poly-N-isoproplyacrylamide nanoparticles dyed with Reactive Blue-221 to concentrate antigens, substantially increasing the limit of detection. After nanoparticle-concentration, a standard western blotting technique with a monoclonal antibody was used for antigen detection. Toxoplasma gondii IgG serological status was determined with an in-house enzyme linked immunosorbent assay (ELISA). For qPCR, target sequences were amplified using a Light Cycler (Applied Biosciences, Foster City, CA, USA). Digested samples were analyzed by parallel-reaction-monitoring (PRM) on an Orbitrap Fusion mass spectrometer with a nanospray EASY-nLC 1200 HPLC (Thermo Fisher Scientific, Waltham, MA, USA).

The team reported that the limit of detection (LoD) of T. gondii antigens GRA1 and SAG1 was 7.8pg/mL and 31.3pg/mL, respectively. To characterize this diagnostic approach, 164 hospitalized HIV-infected patients with neurological symptoms compatible with TE were tested for 1) T. gondii serology (121/147, positive samples/total samples tested), 2) qPCR in cerebrospinal fluid (11/41), 3) qPCR in blood (10/112), and 4) urinary GRA1 (30/164) and SAG1 (12/164). GRA1 appears to be superior to SAG1 for detection of TE antigens in urine. Fifty-one HIV-infected, T. gondii seropositive but asymptomatic persons all tested negative by nanoparticle western blot and blood qPCR, suggesting the test has good specificity for TE for both GRA1 and SAG1. In a subgroup of 44 patients, urine samples were assayed with mass spectrometry PRM for the presence of T. gondii antigens. PRM identified antigens in eight samples, six of which were concordant with the urine diagnostic.

The authors concluded that their results demonstrate nanoparticle technology’s potential for a noninvasive diagnostic test for TE and that GRA1 is a promising target for antigen based diagnostics for TE. The study was published on March 2, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Illinois Chicago
Applied Biosciences
Thermo Fisher Scientific


New
Gold Supplier
SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG
New
Gold Supplier
Molecular & Immunoassay Diagnostic Analyzer
Randox Discovery
New
Reagent Strips
ETEST
New
SARS-CoV-2 S1/S2 IgG Assay
LIAISON SARS-CoV-2 S1/S2 IgG

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.